Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

No search term entered. 243 results shown below.

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

[Complete title: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1409.00
Phase: I/II

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

[Complete title: Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil]
Principal Investigator: Ann Woolfrey, MD
Study Number: 1410.00
Phase: I

Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

[Complete title: Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia – a Multi-Center Trial]
Principal Investigator: George Georges, MD
Study Number: 1581.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients with Advanced AML or High Risk Myelodysplastic Syndrome]
Principal Investigator: John Pagel, MD, PhD
Study Number: 1809.00
Phase: II

Fludarabine, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

[Complete title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 1840.00
Phase: II

Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

[Complete title: Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells for Patients with Malignant Gliomas]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2000.00
Phase: I/II

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

[Complete title: Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2007.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders

[Complete title: HLA-Haploidentical Related Marrow Grafts for the Treatment of Immunodeficiency and Other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, 200 cGy TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus.]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2032.00
Phase: II

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

[Complete title: Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia]
Principal Investigator: Joachim Deeg, MD
Study Number: 2051.00
Phase: I/II

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

[Complete title: Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2056.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2064.00
Phase: II

Nonmyeloablative transplant for severe systemic sclerosis

[Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2067.00
Phase: I/II

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

[Complete title: Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2070.00
Phase: II

Gene Therapy for Fanconi Anemia

[Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 2097.00
Phase: I

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

[Complete title: A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2222.00
Phase: II

Laboratory-Treated T Cells With or Without Ipilimumab in Treating Patients With Metastatic Melanoma

[Complete title: Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and anti-CTLA4 For Patients With Metastatic Melanoma]
Principal Investigator: Aude Chapuis, MD
Study Number: 2225.00
Phase: I/II

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma

[Complete title: Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Relapsed or Refractory CD20+ B-Cell Malignancies]
Principal Investigator: Andrew Rezvani, MD
Study Number: 2226.00
Phase: II

Azacitidine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

[Complete title: Treatment of Post-Transplant Relapse and Persistent Disease in Patients with MDS, CMML and AML with Azacitidine]
Principal Investigator: Bart Scott, MD
Study Number: 2240.00
Phase: II

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2256.00
Phase: II

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

[Complete title: Bortezomib and Vorinostat as Maintenance Therapy after Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2292.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: Hematopoietic Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2309.00
Phase: I

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

[Complete title: Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2310.00
Phase: II

Montelukast to Treat Bronchiolitis Obliterans

[Complete title: Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults]
Principal Investigator: Paul Martin, MD
Study Number: 2317.00
Phase: II

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

[Complete title: A Randomized Placebo Controlled Double-Blind Study of Restasis® Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation]
Principal Investigator: Mary Flowers, MD
Study Number: 2321.00
Phase: III

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

[Complete title: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation]
Principal Investigator: Mary Flowers, MD
Study Number: 2343.00
Phase: II

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

[Complete title: A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2361.00
Phase: I

Chronic Graft-versus-Host Disease Treatment

[Complete title: A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Paul Carpenter, MD
Study Number: 2375.00
Phase: II/III

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Boglarka Gyurkocza, MD
Study Number: 2430.00
Phase: II

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

[Complete title: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2434.00
Phase: III

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2450.00
Phase: I

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

[Complete title: A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL with Lenalidomide alone or with Rituximab]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2467.00
Phase: II

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2468.00
Phase: I

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

[Complete title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)]
Principal Investigator: Bill Bensinger, MD
Study Number: 2477.00
Phase: III

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma

[Complete title: AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2483.00
Phase: I/II

Autologous Transplant in HIV Patients (BMT CTN 0803)

[Complete title: High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-Infected Patients. BMT-CTN Protocol 0803 (AMC 071)]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2485.00
Phase: II

Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

[Complete title: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia]
Principal Investigator: Bart Scott, MD
Study Number: 2497.00
Phase: III

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

[Complete title: Phase I/II study of adoptive immunotherapy with virus specific CD8+ T cells that have been transduced to express a WT1-specific T cell receptor for patients with high risk or relapsed AML, MDS, or CML]
Principal Investigator: Merav Bar, MD
Study Number: 2498.00
Phase: I/II

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

[Complete title: A Phase II study of subcutaneous bortezomib as maintenance therapy for patients with high-risk acute myeloid leukemia in remission]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2529.00
Phase: II

Scleroderma Treatment with Autologous Transplant (STAT) Study

[Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2533.00
Phase: II

Autologous T Cells, Low-Dose Recombinant Interferon Gamma, Cyclophosphamide, and Low-Dose Aldesleukin in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

[Complete title: A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 2537.00
Phase: I

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

[Complete title: A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2541.00
Phase: II

Crohn's Allogeneic Transplant Study (CATS)

[Complete title: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH TREATMENT-REFRACTORY CROHN’S DISEASE: A PHASE 2 STUDY]
Principal Investigator: George McDonald, MD
Study Number: 2551.00
Phase: II

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: A Phase II Study of Tosedostat in Combination with either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2566.00
Phase: II

Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2584.00
Phase: Pilot

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

[Complete title: Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma]
Principal Investigator: Aude Chapuis, MD
Study Number: 2586.00
Phase: I

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

[Complete title: Phase II Trial Examining Epigenetic Priming with Decitabine followed by Idarubicin and Cytarabine for Patients with Relapsed or Refractory AML]
Principal Investigator: Derek Stirewalt, MD
Study Number: 2588.00
Phase: II

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

[Complete title: A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine]
Principal Investigator: K.Scott Baker
Study Number: 2598.00
Phase: II

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2603.00
Phase: II

Internet and Social-Media Program for Improving Quality of Life in Long-Term Cancer Survivors Who Underwent Stem Cell Transplant

[Complete title: INSPIRE for Survivorship after Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-media Program for Long-term Hematopoietic Cell Transplantation Survivors]
Principal Investigator: Karen Syrjala, PhD
Study Number: 2605.00
Phase: III

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2609.00
Phase: NA

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

[Complete title: Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality]
Principal Investigator: Roland Walter, MD
Study Number: 2642.00
Phase: Pilot

Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study]
Principal Investigator: Roland Walter, MD
Study Number: 2652.00
Phase: I/II

Palliative Care Support for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

[Complete title: Feasibility of Implementing Pre-Transplant Palliative Care Support for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2659.00
Phase: Pilot

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

[Complete title: Initial cytoreductive therapy for myelodysplastic syndrome prior to allogeneic hematopoietic cell transplantation (the ICT-HCT Study)]
Principal Investigator: Bart Scott, MD
Study Number: 2661.00
Phase: II

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

[Complete title: Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)]
Principal Investigator: Raya Mawad
Study Number: 2674.00
Phase: II

SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients
Principal Investigator: Monique Cherrier, PhD
Study Number: 30824
Phase: NA

Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

[Complete title: A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients with Locally Advanced, Resectable Pancreatic Adenocarcinoma]
Principal Investigator: Andrew Coveler, MD
Study Number: 6511
Phase: II

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

[Complete title: A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 6620
Phase: II

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

[Complete title: Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib]
Principal Investigator: Jennifer Specht, MD
Study Number: 6628
Phase: II

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

[Complete title: Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 6658
Phase: I/II

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

[Complete title: A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated with Single Agent Targretin]
Principal Investigator: Andrei Shustov, MD
Study Number: 6914
Phase: II

Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer

[Complete title: Molecular correlates of sensitivity and resistance to therapy in prostate cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 6932
Phase: NA

High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer

[Complete title: Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Leptomeningeal Metastases with or without Parenchymal Brain Involvement]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 6954
Phase: II

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

[Complete title: A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial)]
Principal Investigator: Nicole Urban, Sc.D., ScD
Study Number: 6973
Phase: NA

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

[Complete title: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung]
Principal Investigator: Robin Jones
Study Number: 7008
Phase: II

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

[Complete title: Multicenter Selective Lymphadenectomy Trial II (MSLT II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node]
Principal Investigator: David Byrd, MD
Study Number: 7108
Phase: III

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

[Complete title: Phase I Study of ABT-888 in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7161
Phase: I

Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

[Complete title: A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7248
Phase: II

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

[Complete title: Phase II trial of bevacizumab in patients with recurrent or progressive meningiomas]
Principal Investigator: Marc Chamberlain, MD
Study Number: 7329
Phase: II

Vaccine Therapy in Treating Patients With Stage III-IV Ovarian Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients with Advanced Ovarian Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 7396
Phase: I

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

[Complete title: Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)]
Principal Investigator: Laura Chow
Study Number: 7406
Phase: I

Vaccine Therapy in Combination With Ampligen® and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer

[Complete title: Phase I-II Study of HER2 Vaccination with poly(I)* poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients]
Principal Investigator: Lupe Salazar, MD
Study Number: 7425
Phase: I/II

Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

[Complete title: The Effect of Antiangiogenic Therapy with Pazopanib Prior to Preoperative Chemotherapy for Subjects with Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging]
Principal Investigator: Robin Jones
Study Number: 7487
Phase: Pilot

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

[Complete title: A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer]
Principal Investigator: Shilpen Patel, MD
Study Number: 7506
Phase: I

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

[Complete title: I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)]
Principal Investigator: Larissa Korde
Study Number: 7518
Phase: II

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

[Complete title: A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake]
Principal Investigator: Laura Chow
Study Number: 7529
Phase: I

Phenelzine Sulfate and Docetaxel for Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

[Complete title: A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy]
Principal Investigator: Evan Yu, MD
Study Number: 7563
Phase: II

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen

[Complete title: Multi-center, single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) regimen]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7617
Phase: II

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 7639
Phase: II

Capecitabine and Celecoxib With or Without Radiation Therapy in Treating Patients With Colorectal Cancer Previously Treated With Fluorouracil

[Complete title: A Phase II Trial of Maintenance ADAPT Therapy with Capecitabine and Celecoxib in Patients with Metastatic Colorectal Cancer]
Principal Investigator: Edward Lin, MD
Study Number: 7707
Phase: II

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Ovarian Cancer Survivors

[Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study]
Principal Investigator: Heidi Gray, MD
Study Number: 7750
Phase: Pilot

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

[Complete title: A Phase II Study of Carboplatin, Nab-Paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 7797
Phase: II

Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

[Complete title: A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Refractory to Every > = 3 Week Brentuximab Vedotin]
Principal Investigator: Ajay Gopal, MD
Study Number: 7808
Phase: Pilot

Cabozantinib in Treating Men With Hormone-Resistant Prostate Cancer

[Complete title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 7819
Phase: Pilot

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

[Complete title: A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B]
Principal Investigator: Hannah Linden, MD
Study Number: 7841
Phase: Pilot

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 7847
Phase: II

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

[Complete title: Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer]
Principal Investigator: Lupe Salazar, MD
Study Number: 7905
Phase: II

International Collaborative Treatment Protocol For Infants Under One Year With Acute Lymphoblastic Or Biphenotypic Leukemia
Principal Investigator: Blythe Thomson, MD
Study Number: CHRMC 2006
Phase: III

Efficacy of Carboplatin Administered Concomitantly with Radiation and Isoretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: James Olson, MD, PhD
Study Number: COG ACNS0332
Phase: III

European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99)
Principal Investigator: Doug Hawkins, MD
Study Number: COG AEWS0331
Phase: III

Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma
Principal Investigator: Julie Park, MD
Study Number: COG ANBL0532
Phase: III

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARST0531
Phase: III

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0724/ RTOG 0724
Phase: III

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic

[Complete title: A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)]
Principal Investigator: John Pagel, MD, PhD
Study Number: PSOC 2401
Phase: I/II

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: I/II

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer

[Complete title: A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1898.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

[Complete title: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies: A Multi-Center Trial Coordinated by the FHCRC]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2044.00
Phase: I

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After Transplantation]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2186.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

[Complete title: Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2212.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin

[Complete title: A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2238.00
Phase: I

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2239.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

[Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases]
Principal Investigator: George Georges, MD
Study Number: 2260.00
Phase: I/II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2275.00
Phase: II

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

[Complete title: Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematological Malignancies: a Multi-Center Study]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2284.00
Phase: I

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

[Complete title: Longitudinal Study of Immune Mediated Disorders after Allogeneic HCT]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2342.00
Phase: NA

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

[Complete title: Targeted Therapy of Bronchiolitis Obliterans Syndrome]
Principal Investigator: Paul Martin, MD
Study Number: 2367.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Paul O'Donnell, MD, PhD
Study Number: 2372.00
Phase: II

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2448.00
Phase: III

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

[Complete title: A Phase I/II Study of Cellular Immunotherapy with Donor Central Memory-Derived Virus-Specific CD8+ T-Cells Engineered to Target CD19 for CD19+ Malignancies after Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 2494.00
Phase: I/II

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

[Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2531.00
Phase: NA

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2545.00
Phase: II

Donor Atorvastatin -Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Double Cord vs. Haploidentical (BMT CTN #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Paul O'Donnell, MD, PhD
Study Number: 2580.00
Phase: III

Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease

[Complete title: A Phase II Study of Bandage Lenses for Ocular Graft-versus-host Disease after Allogeneic Hematopoietic Cell Transplantation]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2617.00
Phase: II

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

[Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2639.00
Phase: I/II

Bendamustine Hydrochloride, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

[Complete title: A Phase II Study of Bendamustine (B), Etoposide (E) Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)]
Principal Investigator: Ajay Gopal, MD
Study Number: 7176
Phase: II

Cognitive Rehabilitation in Cancer Survivors: A Pilot Study
Principal Investigator: Monique Cherrier, PhD
Study Number: 7279
Phase: NA

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

[Complete title: PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 7591
Phase: II

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

[Complete title: Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 7674
Phase: II

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas

[Complete title: A Phase I/II Trial of Bendamustine/Treanda, Rituximab, Etoposide and Carboplatin for Patients with Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)]
Principal Investigator: Ajay Gopal, MD
Study Number: PSOC 2502
Phase: I

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
Principal Investigator: George Laramore, MD, PhD
Study Number: 6864
Phase: III

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

[Complete title: Phase III Study of Radiation Therapy With or Without Temozolomide For Symptomatic or Progressive Low-Grade Gliomas CCIRB#7269]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7294
Phase: III

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer
Principal Investigator: George Laramore, MD, PhD
Study Number: 7428
Phase: III

A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer
Principal Investigator: George Laramore, MD, PhD
Study Number: 7585
Phase: III

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer

[Complete title: A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7637a
Phase: I

RTOG 0926 A Phase II Protocol For Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging.
Principal Investigator: George Laramore, MD, PhD
Study Number: 7684
Phase: II

RTOG 0834: Phase III Trial On Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The CATNON Intergroup Trial
Principal Investigator: George Laramore, MD, PhD
Study Number: 7880
Phase: III

Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Principal Investigator: Blythe Thomson, MD
Study Number: COG AALL0434
Phase: III

A Study of Neurocognitive Function in Children Treated for ALL. A Group-wide, Non-therapeutic Companion Study to AALL0232 and AALL0434
Principal Investigator: Doug Hawkins, MD
Study Number: COG AALL06N1
Phase: NA

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Principal Investigator: J. Russell Geyer, MD
Study Number: COG ACNS0331
Phase: III

A Phase I study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in children with refractory solid tumors or refractory leukemias
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0413
Phase: I

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

Phase III, Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High-Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Principal Investigator: Julie Park, MD
Study Number: COG ANBL0032
Phase: III

A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone
Principal Investigator: Julie Park, MD
Study Number: COG ANBL00P3
Phase: III

Treatment of Adrenocortical Tumors with Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARAR0332
Phase: III

Treatment of High Risk Renal Tumors; A Groupwide Phase II Study.
Principal Investigator: Doug Hawkins, MD
Study Number: COG AREN0321
Phase: II

Treatment for Very Low, Low, and Standard Risk Favorable Histology Wilms Tumor. A Groupwide Phase III Study
Principal Investigator: Doug Hawkins, MD
Study Number: COG AREN0532
Phase: III

Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Principal Investigator: Doug Hawkins, MD
Study Number: COG AREN0533
Phase: III

A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARET0231
Phase: III

Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARST0332
Phase: III

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel (CT-2103) (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0212
Phase: III

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC#704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0213
Phase: II/III

A Phase II Evaluation of Dalantercept, A Novel Soluable Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in Treatment of Recurrent or Persistent Endometrial Carcinoma
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0229-N
Phase: II

A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0249
Phase: II/III

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0258
Phase: III

A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0261
Phase: III

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0268
Phase: II

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68254)
Principal Investigator: Julie Park, MD
Study Number: NANT 2004-04
Phase: I

Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Resistant/Recurrent High-Risk Neuroblastoma (IND #69,112)
Principal Investigator: Julie Park, MD
Study Number: NANT 9902
Phase: I

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-39
Phase: III

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-43
Phase: III

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-47
Phase: III

Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP P-5
Phase: III

Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

[Complete title: A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment]
Principal Investigator: Robin Jones
Study Number: 20051530
Phase: III

A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

[Complete title: A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects with Advanced Renal Cell Carcinoma]
Principal Investigator: John Thompson, MD
Study Number: 20100220
Phase: I

Study of MLN8237 in Patients With Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen

[Complete title: A Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, or No MLN8237 in Patients with Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen, Preceded by a Phase I Dose-Escalation Study - Part 1 and 2]
Principal Investigator: Tia Higano, MD
Study Number: 20100481
Phase: II

First in Human Study to Determine the Safety, Tolerability and Preliminary Effectiveness of MDX-1338 (BMS 936564) in Subjects With Acute Myelogenous Leukemia (AML)

[Complete title: A Phase 1, Open-Label, Multicenter Study of MDX-1338/BMS936564 in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20100803
Phase: I

A Study in Second Line Metastatic Colorectal Cancer

[Complete title: A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine]
Principal Investigator: Veena Shankaran
Study Number: 20101327
Phase: III

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

[Complete title: An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC 1121B) Drug Product or IMC 18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy]
Principal Investigator: Evan Yu, MD
Study Number: 20101692
Phase: II

A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

[Complete title: A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)]
Principal Investigator: Laura Chow
Study Number: 20110186
Phase: I

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced L-sarcoma

[Complete title: A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide]
Principal Investigator: Robin Jones
Study Number: 20110545
Phase: III

A Phase 1 Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

[Complete title: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20110853
Phase: II

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)

[Complete title: A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111067
Phase: III

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

[Complete title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111239
Phase: I/II

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

[Complete title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma]
Principal Investigator: Robin Jones
Study Number: 20111252
Phase: III

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

[Complete title: Gilead GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111441
Phase: II

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

[Complete title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20111531
Phase: III

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

[Complete title: An Open-Label, Phase 2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-Positive Acute Lymphocytic Leukemia]
Principal Investigator: Andrei Shustov, MD
Study Number: 20111581
Phase: II

A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

[Complete title: Open-Label Multicenter Phase I Study of RO5429083 with Dose-Escalation and Extension Cohorts in Patients with Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111743
Phase: I

Previous Study | Return to List | Next Study A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

[Complete title: A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20111765
Phase: II

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

[Complete title: Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20111792
Phase: I/II

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

[Complete title: A Phase 1b, Open-label, Multicenter Study of BMS-936564 in Combination with Lenalidomide (Revlimid®) plus low-dose Dexamethasone, or with Bortezomib (Velcade®) plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20111816
Phase: I

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

[Complete title: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine]
Principal Investigator: Jennifer Specht, MD
Study Number: 20111824
Phase: III

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

[Complete title: A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20111942
Phase: I

Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

[Complete title: A Phase II Trial to Evaluate the Efficacy of Fostamatinib inPatients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20111975
Phase: II

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

[Complete title: Randomized, Phase II, Multicenter, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients with Stage IIIB (T4 Disease) or IV Squamous Non–Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20111995
Phase: II

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

[Complete title: A Randomized, Phase II, Multicenter, Double Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First-Line Treatment in Patients with Stage IIIB or IV Non Squamous Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20111997
Phase: II

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects =/> 60 Years Old With Newly Diagnosed ALL

[Complete title: A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20112071
Phase: III

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

[Complete title: A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma]
Principal Investigator: Evan Yu, MD
Study Number: 20120003
Phase: II

ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

[Complete title: POLARIS2009-001: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20120106
Phase: III

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

[Complete title: A Phase 3 Randomized, Two-Arm, Open Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 20120291
Phase: III

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

[Complete title: A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20120892
Phase: I

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer (STRIVE)

[Complete title: STRIVE: A multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs Bicalutamide in Men with Prostate Cancer who have Failed Primary Androgen Deprivation Therapy]
Principal Investigator: Tia Higano, MD
Study Number: 20120956
Phase: II

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

[Complete title: A multi-arm dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3-K) inhibitor BKM120 in patients with Gastrointestinal Stromal Tumor (GIST) who failed prior therapy with imatinib and sunitinib]
Principal Investigator: Robin Jones
Study Number: 20121008
Phase: I

A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

[Complete title: A Phase II, Multicenter, Open-Label, Randomized Study Evaluating The Efficacy And Safety Of Folfiri + Mehd7945a Versus Folfiri + Cetuximab In Second Line In Patients With Kras Wild-Type Metastatic Colorectal Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 20121026
Phase: II

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

[Complete title: A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP30862 in Patients with Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20121064
Phase: I

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

[Complete title: A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination with Everolimus in Patients with CD70-Positive Metastatic Renal Cell Carcinoma]
Principal Investigator: John Thompson, MD
Study Number: 20121070
Phase: I

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

[Complete title: A Phase I, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma of Clear Cell or Papillary Histology]
Principal Investigator: John Thompson, MD
Study Number: 20121076
Phase: I

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

[Complete title: A Two-Cohort, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination with Trastuzumab and Vinorelbine in First Line Patients with HER2-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 20121111
Phase: II

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE)

[Complete title: A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma]
Principal Investigator: Robin Jones
Study Number: 20121175
Phase: II

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

[Complete title: Randomized Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma]
Principal Investigator: Kim Margolin, MD
Study Number: 20121298
Phase: II

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

[Complete title: An Open-label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20121428
Phase: III

A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

[Complete title: A PhaseI/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20121484
Phase: I/II

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

[Complete title: An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20121498
Phase: III

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM3)

[Complete title: A Phase 2 Assessment of the Diagnostic Accuracy of Tc-MIP-1404 Imaging in Men with High-Risk Prostrate Cancer Scheduled for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection Compared to Histopathology]
Principal Investigator: William Ellis
Study Number: 20121505
Phase: II

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

[Complete title: A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20121654
Phase: I/II

Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC

[Complete title: A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy]
Principal Investigator: Scott Tykodi, MD
Study Number: 20121671
Phase: III

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

[Complete title: An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20122036
Phase: I

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

[Complete title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy.]
Principal Investigator: Evan Yu, MD
Study Number: 20122140
Phase: II

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

[Complete title: An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2388.00
Phase: III

A Phase 1/2 Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Phase 1/2 Study Of Arry-520 In Patients With Relapsed Or Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2402.00
Phase: I/II

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

[Complete title: A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2487.00
Phase: I

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

[Complete title: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy]
Principal Investigator: Scott Tykodi, MD
Study Number: 2489.00
Phase: III

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

[Complete title: An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman’s Disease]
Principal Investigator: Corey Casper
Study Number: 2502.00
Phase: II

A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carflizomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2512.00
Phase: I

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

[Complete title: A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia-2 (CMML-2), Myelodysplasic Syndrome Having Failed Hypomethylating Treatment (MDS) and High-Risk Myelofibrosis (MF)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2513.00
Phase: I

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

[Complete title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2521.00
Phase: III

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

[Complete title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2522.00
Phase: III

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

[Complete title: A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults with Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2532.00
Phase: I/II

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

[Complete title: A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine]
Principal Investigator: Bart Scott, MD
Study Number: 2534.00
Phase: III

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

[Complete title: A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)]
Principal Investigator: Paul Martin, MD
Study Number: 2538.00
Phase: I/II

Previous Study | Return to List | Next Study Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients

[Complete title: A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2572.00
Phase: I/II

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Phase 1b Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (WIRB 20120285, Study 1132239)]
Principal Investigator: Vivian Oehler, MD
Study Number: 2592.00
Phase: I/II

A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

[Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2597.00
Phase: III

A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma (11-MM-01)

[Complete title: A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2599.00
Phase: I

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

[Complete title: A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections that are Resistant or Refractory to Treatment with Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipient]
Principal Investigator: Michael Boeckh, MD
Study Number: 2601.00
Phase: II

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

[Complete title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2606.00
Phase: III

A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

[Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2612.00
Phase: III

A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

[Complete title: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2613.00
Phase: III

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

[Complete title: A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse]
Principal Investigator: Roland Walter, MD
Study Number: 2616.00
Phase: I

An Open Label Study to Evaluate the Safety and Efficacy of Two Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: A Phase 2, Randomized, Open-label study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2623.00
Phase: II

Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia

[Complete title: A Phase 1b, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2631.00
Phase: I

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (DEFLECT-1)

[Complete title: DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against CLostridium difficilE-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation]
Principal Investigator: Steven Pergam, MD
Study Number: 2634.00
Phase: III

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

[Complete title: A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase]
Principal Investigator: Vivian Oehler, MD
Study Number: 2645.00
Phase: III

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

[Complete title: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination with Rituximab or DCDS4501A in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2649.00
Phase: II

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

[Complete title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75Yyears of Age with Untreated High Risk (secondary) AML]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2651.00
Phase: III

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

[Complete title: A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2672.00
Phase: II

Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)

[Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)]
Principal Investigator: Scott Tykodi, MD
Study Number: 7104
Phase: I

Immunotherapy Study for Surgically Resected Pancreatic Cancer

[Complete title: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute ® Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 7259
Phase: III

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

[Complete title: Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 7334
Phase: III

MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

[Complete title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 7527
Phase: I/II

Previous Study | Return to List | Next Study Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

[Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy]
Principal Investigator: William Harris
Study Number: 7627
Phase: III

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)

[Complete title: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus chemotherapy Followed by Rituximab in subjects with Previously Untreated Follicular Lymphoma (The “RELEVANCE” Trial)]
Principal Investigator: Edward Libby
Study Number: 7636
Phase: III

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (ESP2011-002)

[Complete title: EP-100, a Novel LHRH Receptor-Targeted Membrane-Disruptive Peptide, plus Paclitaxel® versus Paclitaxel® alone for Refractory or Recurrent Ovarian Cancer: a Phase II, Randomized, Multi-Center Trial]
Principal Investigator: Renata Urban
Study Number: 7685
Phase: I/II

Trial of pIL-12 Electroporation Malignant Melanoma (IL12MEL)

[Complete title: A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7703
Phase: II

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

[Complete title: Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7712
Phase: I/II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.